Reports

Industry Research Reports

Home > Reports > Medical Care > Peptide Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032

Peptide Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032

Peptide Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032

Industry: Medical Care

Published Date: 2026-02-14

Pages: 122 Pages

Report ld: 5493417

application for samples

Request Sample

Custom reports

Customized Report

  • Description selected
  • Table of Contents selected
  • Table of Figures selected
  • Related Reports selected
  • PDFPDF Downloadselected
  • Description selected
  • Table of Contents selected
  • Table of Figures selected
  • Related Reports selected
  • PDFPDF Downloadselected

Peptide Therapeutics Market Size(US$)

den_QYR1
cagr

CAGR 2026-2032

9.0%

marketSize

Market Size,2032

USD 80,340

Million

Market Snapshot

Market Size in 2026 (Value)
US$ 47,910 million
Market Forecast in 2032(Value)
US$ 80,340 million
CAGR
9.0%
Years Considered
2021-2032
Base Year
2026
Forecast Period
2026-2032

Source: Secondary research, interviews with experts, and QYResearch analysis

The global market for Peptide Therapeutics was estimated to be worth US$ 44320 million in 2025 and is projected to reach US$ 80340 million, growing at a CAGR of 9.0% from 2026 to 2032.

Peptide therapeutics are a class of pharmaceutical drugs composed of short chains of amino acids, typically ranging from 2 to 50 residues, that mimic natural peptides in the body. These drugs are designed to interact with specific cellular targets, such as receptors, enzymes, or ion channels, to regulate physiological functions. Due to their high specificity, low toxicity, and favorable safety profiles, peptide drugs are widely used in the treatment of various diseases, including cancer, diabetes, cardiovascular diseases, and infectious conditions. With advances in peptide engineering, formulation, and delivery technologies, peptide therapeutics have become a growing segment of the biopharmaceutical industry.The average gross profit margin of this product is 70%.

The Peptide Therapeutics market is driven by the increasing demand for highly specific and efficient treatments for a wide range of diseases, including cancer, diabetes, cardiovascular conditions, and rare genetic disorders. Peptides, due to their high selectivity, low immunogenicity, and close resemblance to natural biological molecules, are well-suited for targeted therapy with fewer side effects. Technological advancements in peptide synthesis, modification, and drug delivery systems have enhanced their stability and extended their half-life, making them more viable for clinical use. Additionally, the growing investment in biopharmaceutical research and development, along with a favorable regulatory environment for innovative therapies, is accelerating the development and approval of peptide-based drugs.

Despite these advantages, the Peptide Therapeutics market faces several challenges, particularly related to drug delivery and manufacturing. Peptides are generally unstable in the gastrointestinal tract and are rapidly degraded by enzymes, limiting their oral bioavailability and often requiring parenteral administration. This can affect patient compliance and limit market penetration. Moreover, the complex and costly manufacturing processes for peptide drugs, including synthesis, purification, and formulation, pose economic and technical barriers, especially for smaller biotech firms. Overcoming these limitations through innovative formulation strategies and cost-efficient production methods is critical for ensuring broader clinical adoption and long-term market growth.

This report provides a comprehensive view of the global market for Peptide Therapeutics, covering total sales revenue, the market share and ranking of key companies, along with analyses by region & country, by Type, and by Application.

The Peptide Therapeutics market size, estimations, and forecasts are presented in terms of sales revenue ($ millions), with 2025 as the base year and historical and forecast data from 2021 to 2032. The report combines quantitative and qualitative analysis to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current marketplace, and make informed business decisions regarding Peptide Therapeutics.

MARKET SEGMENTATION

By Company

  • Sanofi
  • Teva
  • Novo Nordisk
  • Takeda
  • Eli Lilly
  • AstraZeneca
  • Novartis
  • AbbVie
  • Ipsen
  • Ferring
  • Merck
  • The Medicines
  • J & J
  • Aurinia Pharmaceuticals
  • BioMarin Pharmaceutical
  • Apellis Pharmaceuticals
  • Lantheus
  • CSL Vifor Group

Consumption by Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Segment by Type

  • Injection
  • Oral
  • Other

Segment by Application

  • Cancer
  • Metabolic Disorders
  • Central Nervous System
  • Other

Segment by Category

  • Agonist/Analog
  • Antagonist
  • Enzyme Inhibitor
  • Ion Channel

Segment by Division

  • Retail
  • Hospital
  • Other

biaoTi CHAPTER OUTLINE

marn_i1

Chapter 1: Introduces the scope of the report and the global market size (value). It also summarizes market dynamics and recent developments; identifies key drivers and restraints; outlines challenges and risks for players; reviews relevant industry policies.

marn_i1

Chapter 2: Provides a detailed analysis of the Peptide Therapeutics companies' competitive landscape—including revenue shares, recent development plans, and mergers and acquisitions (M&A).

marn_i1

Chapter 3: Analyzes market segmentation by Type, presenting the size and growth potential of each segment to help readers identify blue-ocean opportunities.

marn_i1

Chapter 4: Analyzes market segmentation by Application, presenting the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.

marn_i1

Chapter 5: Presents Peptide Therapeutics revenue at the regional level. It offers a quantitative assessment of market size and growth potential by region and summarizes market development, future prospects, addressable space, and country-level market size worldwide.

marn_i1

Chapter 6: Presents Peptide Therapeutics revenue at the country level. It provides segmented data by Type and by Application for each country/region.

marn_i1

Chapter 7: Profiles key players, detailing the main companies' product revenue, gross margin, product portfolios, recent developments, etc.

marn_i1

Chapter 8: Analysis of Value Chain, including the upstream and downstream of the industry.

marn_i1

Chapter 9: Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region
Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

den_ic6
Product mix optimization based on local practices
Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

den_ic6
Competitor tactics in fragmented vs. consolidated markets
Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

den_ic6
Full Research Coverage
Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

den_ic6
19 Years Industry Expertise
19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

den_ic6
24/7 Fast Report Delivery
24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

den_ic6
Localized Strategic Analysis
Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

den_ic6
Market entry risks/opportunities by region
Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

den_ic6
Market entry risks/opportunities by region
Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

den_ic6
den_biaoTiZhungShi

TABLE OF CONTENTS

muLu

1 Market Overview

1.1 Peptide Therapeutics Product Introduction

1.2 Global Peptide Therapeutics Market Size Forecast (2021–2032)

1.3 Peptide Therapeutics Market Trends & Drivers

1.3.1 Peptide Therapeutics Industry Trends

1.3.2 Peptide Therapeutics Market Drivers & Opportunities

1.3.3 Peptide Therapeutics Market Challenges

1.3.4 Peptide Therapeutics Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

muLu

2 Competitive Analysis by Company

2.1 Global Peptide Therapeutics Players Revenue Ranking (2025)

2.2 Global Peptide Therapeutics Revenue by Company (2021–2026)

2.3 Key Companies’ R&D and Operations Footprint and Headquarters

2.4 Key Companies Peptide Therapeutics Product Offerings

2.5 Key Companies General Availability (GA) Timeline for Peptide Therapeutics

2.6 Peptide Therapeutics Market Competitive Analysis

2.6.1 Peptide Therapeutics Market Concentration Rate (2021–2026)

2.6.2 Top 5 and Top 10 Global Companies by Peptide Therapeutics Revenue in 2025

2.6.3 Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on Peptide Therapeutics revenue, 2025

2.7 Mergers & Acquisitions and Expansion

muLu

3 Segmentation Peptide Therapeutics Market Classification

3.1 Introduction by Type

3.1.1 Injection

3.1.2 Oral

3.1.3 Other

3.1.4 Global Peptide Therapeutics Sales Value by Type

3.1.4.1 Global Peptide Therapeutics Sales Value by Type (2021 vs 2025 vs 2032)

3.1.4.2 Global Peptide Therapeutics Sales Value, by Type (2021–2032)

3.1.4.3 Global Peptide Therapeutics Sales Value, by Type (%), 2021–2032

3.2 Introduction by Target Class

3.2.1 Agonist/Analog

3.2.2 Antagonist

3.2.3 Enzyme Inhibitor

3.2.4 Ion Channel

3.2.5 Global Peptide Therapeutics Sales Value by Target Class

3.2.5.1 Global Peptide Therapeutics Sales Value by Target Class (2021 vs 2025 vs 2032)

3.2.5.2 Global Peptide Therapeutics Sales Value, by Target Class (2021–2032)

3.2.5.3 Global Peptide Therapeutics Sales Value, by Target Class (%), 2021–2032

3.3 Introduction by End Users

3.3.1 Retail

3.3.2 Hospital

3.3.3 Other

3.3.4 Global Peptide Therapeutics Sales Value by End Users

3.3.4.1 Global Peptide Therapeutics Sales Value by End Users (2021 vs 2025 vs 2032)

3.3.4.2 Global Peptide Therapeutics Sales Value, by End Users (2021–2032)

3.3.4.3 Global Peptide Therapeutics Sales Value, by End Users (%), 2021–2032

muLu

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Cancer

4.1.2 Metabolic Disorders

4.1.3 Central Nervous System

4.1.4 Other

4.2 Global Peptide Therapeutics Sales Value by Application

4.2.1 Global Peptide Therapeutics Sales Value by Application (2021 vs 2025 vs 2032)

4.2.2 Global Peptide Therapeutics Sales Value by Application (2021–2032)

4.2.3 Global Peptide Therapeutics Sales Value by Application (%), 2021–2032

muLu

5 Segmentation by Region

5.1 Global Peptide Therapeutics Sales Value by Region

5.1.1 Global Peptide Therapeutics Sales Value by Region: 2021 vs 2025 vs 2032

5.1.2 Global Peptide Therapeutics Sales Value by Region (2021–2026)

5.1.3 Global Peptide Therapeutics Sales Value by Region (2027–2032)

5.1.4 Global Peptide Therapeutics Sales Value by Region (%), 2021–2032

5.2 North America

5.2.1 North America Peptide Therapeutics Sales Value, 2021–2032

5.2.2 North America Peptide Therapeutics Sales Value by Country (%), 2025 vs 2032

5.3 Europe

5.3.1 Europe Peptide Therapeutics Sales Value, 2021–2032

5.3.2 Europe Peptide Therapeutics Sales Value by Country (%), 2025 vs 2032

5.4 Asia Pacific

5.4.1 Asia Pacific Peptide Therapeutics Sales Value, 2021–2032

5.4.2 Asia Pacific Peptide Therapeutics Sales Value by Subregion (%), 2025 vs 2032

5.5 South America

5.5.1 South America Peptide Therapeutics Sales Value, 2021–2032

5.5.2 South America Peptide Therapeutics Sales Value by Country (%), 2025 vs 2032

5.6 Middle East & Africa

5.6.1 Middle East & Africa Peptide Therapeutics Sales Value, 2021–2032

5.6.2 Middle East & Africa Peptide Therapeutics Sales Value by Country (%), 2025 vs 2032

muLu

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Peptide Therapeutics Sales Value Growth Trends, 2021 vs 2025 vs 2032

6.2 Key Countries/Regions Peptide Therapeutics Sales Value, 2021–2032

6.3 United States

6.3.1 United States Peptide Therapeutics Sales Value, 2021–2032

6.3.2 United States Peptide Therapeutics Sales Value by Type (%), 2025 vs 2032

6.3.3 United States Peptide Therapeutics Sales Value by Application, 2025 vs 2032

6.4 Europe

6.4.1 Europe Peptide Therapeutics Sales Value, 2021–2032

6.4.2 Europe Peptide Therapeutics Sales Value by Type (%), 2025 vs 2032

6.4.3 Europe Peptide Therapeutics Sales Value by Application, 2025 vs 2032

6.5 China

6.5.1 China Peptide Therapeutics Sales Value, 2021–2032

6.5.2 China Peptide Therapeutics Sales Value by Type (%), 2025 vs 2032

6.5.3 China Peptide Therapeutics Sales Value by Application, 2025 vs 2032

6.6 Japan

6.6.1 Japan Peptide Therapeutics Sales Value, 2021–2032

6.6.2 Japan Peptide Therapeutics Sales Value by Type (%), 2025 vs 2032

6.6.3 Japan Peptide Therapeutics Sales Value by Application, 2025 vs 2032

6.7 South Korea

6.7.1 South Korea Peptide Therapeutics Sales Value, 2021–2032

6.7.2 South Korea Peptide Therapeutics Sales Value by Type (%), 2025 vs 2032

6.7.3 South Korea Peptide Therapeutics Sales Value by Application, 2025 vs 2032

6.8 Southeast Asia

6.8.1 Southeast Asia Peptide Therapeutics Sales Value, 2021–2032

6.8.2 Southeast Asia Peptide Therapeutics Sales Value by Type (%), 2025 vs 2032

6.8.3 Southeast Asia Peptide Therapeutics Sales Value by Application, 2025 vs 2032

6.9 India

6.9.1 India Peptide Therapeutics Sales Value, 2021–2032

6.9.2 India Peptide Therapeutics Sales Value by Type (%), 2025 vs 2032

6.9.3 India Peptide Therapeutics Sales Value by Application, 2025 vs 2032

muLu

7 Company Profiles

7.1 Sanofi

7.1.1 Sanofi Profile

7.1.2 Sanofi Main Business

7.1.3 Sanofi Peptide Therapeutics Products, Services, and Solutions

7.1.4 Sanofi Peptide Therapeutics Revenue (US$ Million), 2021–2026

7.1.5 Sanofi Recent Developments

7.2 Teva

7.2.1 Teva Profile

7.2.2 Teva Main Business

7.2.3 Teva Peptide Therapeutics Products, Services, and Solutions

7.2.4 Teva Peptide Therapeutics Revenue (US$ Million), 2021–2026

7.2.5 Teva Recent Developments

7.3 Novo Nordisk

7.3.1 Novo Nordisk Profile

7.3.2 Novo Nordisk Main Business

7.3.3 Novo Nordisk Peptide Therapeutics Products, Services, and Solutions

7.3.4 Novo Nordisk Peptide Therapeutics Revenue (US$ Million), 2021–2026

7.3.5 Novo Nordisk Recent Developments

7.4 Takeda

7.4.1 Takeda Profile

7.4.2 Takeda Main Business

7.4.3 Takeda Peptide Therapeutics Products, Services, and Solutions

7.4.4 Takeda Peptide Therapeutics Revenue (US$ Million), 2021–2026

7.4.5 Takeda Recent Developments

7.5 Eli Lilly

7.5.1 Eli Lilly Profile

7.5.2 Eli Lilly Main Business

7.5.3 Eli Lilly Peptide Therapeutics Products, Services, and Solutions

7.5.4 Eli Lilly Peptide Therapeutics Revenue (US$ Million), 2021–2026

7.5.5 Eli Lilly Recent Developments

7.6 AstraZeneca

7.6.1 AstraZeneca Profile

7.6.2 AstraZeneca Main Business

7.6.3 AstraZeneca Peptide Therapeutics Products, Services, and Solutions

7.6.4 AstraZeneca Peptide Therapeutics Revenue (US$ Million), 2021–2026

7.6.5 AstraZeneca Recent Developments

7.7 Novartis

7.7.1 Novartis Profile

7.7.2 Novartis Main Business

7.7.3 Novartis Peptide Therapeutics Products, Services, and Solutions

7.7.4 Novartis Peptide Therapeutics Revenue (US$ Million), 2021–2026

7.7.5 Novartis Recent Developments

7.8 AbbVie

7.8.1 AbbVie Profile

7.8.2 AbbVie Main Business

7.8.3 AbbVie Peptide Therapeutics Products, Services, and Solutions

7.8.4 AbbVie Peptide Therapeutics Revenue (US$ Million), 2021–2026

7.8.5 AbbVie Recent Developments

7.9 Ipsen

7.9.1 Ipsen Profile

7.9.2 Ipsen Main Business

7.9.3 Ipsen Peptide Therapeutics Products, Services, and Solutions

7.9.4 Ipsen Peptide Therapeutics Revenue (US$ Million), 2021–2026

7.9.5 Ipsen Recent Developments

7.10 Ferring

7.10.1 Ferring Profile

7.10.2 Ferring Main Business

7.10.3 Ferring Peptide Therapeutics Products, Services, and Solutions

7.10.4 Ferring Peptide Therapeutics Revenue (US$ Million), 2021–2026

7.10.5 Ferring Recent Developments

7.11 Merck

7.11.1 Merck Profile

7.11.2 Merck Main Business

7.11.3 Merck Peptide Therapeutics Products, Services, and Solutions

7.11.4 Merck Peptide Therapeutics Revenue (US$ Million), 2021–2026

7.11.5 Merck Recent Developments

7.12 The Medicines

7.12.1 The Medicines Profile

7.12.2 The Medicines Main Business

7.12.3 The Medicines Peptide Therapeutics Products, Services, and Solutions

7.12.4 The Medicines Peptide Therapeutics Revenue (US$ Million), 2021–2026

7.12.5 The Medicines Recent Developments

7.13 J & J

7.13.1 J & J Profile

7.13.2 J & J Main Business

7.13.3 J & J Peptide Therapeutics Products, Services, and Solutions

7.13.4 J & J Peptide Therapeutics Revenue (US$ Million), 2021–2026

7.13.5 J & J Recent Developments

7.14 Aurinia Pharmaceuticals

7.14.1 Aurinia Pharmaceuticals Profile

7.14.2 Aurinia Pharmaceuticals Main Business

7.14.3 Aurinia Pharmaceuticals Peptide Therapeutics Products, Services, and Solutions

7.14.4 Aurinia Pharmaceuticals Peptide Therapeutics Revenue (US$ Million), 2021–2026

7.14.5 Aurinia Pharmaceuticals Recent Developments

7.15 BioMarin Pharmaceutical

7.15.1 BioMarin Pharmaceutical Profile

7.15.2 BioMarin Pharmaceutical Main Business

7.15.3 BioMarin Pharmaceutical Peptide Therapeutics Products, Services, and Solutions

7.15.4 BioMarin Pharmaceutical Peptide Therapeutics Revenue (US$ Million), 2021–2026

7.15.5 BioMarin Pharmaceutical Recent Developments

7.16 Apellis Pharmaceuticals

7.16.1 Apellis Pharmaceuticals Profile

7.16.2 Apellis Pharmaceuticals Main Business

7.16.3 Apellis Pharmaceuticals Peptide Therapeutics Products, Services, and Solutions

7.16.4 Apellis Pharmaceuticals Peptide Therapeutics Revenue (US$ Million), 2021–2026

7.16.5 Apellis Pharmaceuticals Recent Developments

7.17 Lantheus

7.17.1 Lantheus Profile

7.17.2 Lantheus Main Business

7.17.3 Lantheus Peptide Therapeutics Products, Services, and Solutions

7.17.4 Lantheus Peptide Therapeutics Revenue (US$ Million), 2021–2026

7.17.5 Lantheus Recent Developments

7.18 CSL Vifor Group

7.18.1 CSL Vifor Group Profile

7.18.2 CSL Vifor Group Main Business

7.18.3 CSL Vifor Group Peptide Therapeutics Products, Services, and Solutions

7.18.4 CSL Vifor Group Peptide Therapeutics Revenue (US$ Million), 2021–2026

7.18.5 CSL Vifor Group Recent Developments

muLu

8 Industry Chain Analysis

8.1 Peptide Therapeutics Value Chain

8.2 Peptide Therapeutics Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Key Suppliers of Raw Materials

8.2.3 Cost Structure

8.3 Midstream Analysis

8.4 Downstream (Customer) Analysis

8.5 Sales Model and Sales Channelss

8.5.1 Peptide Therapeutics Sales Model

8.5.2 Sales Channels

8.5.3 Peptide Therapeutics Distributors

muLu

9 Research Findings and Conclusion

muLu

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

den_biaoTiZhungShi

TABLE OF FIGURES

muLu

List of Tables

Table 1. Peptide Therapeutics Market Trends
Table 2. Peptide Therapeutics Market Drivers & Opportunities
Table 3. Peptide Therapeutics Market Challenges
Table 4. Peptide Therapeutics Market Restraints
Table 5. Global Peptide Therapeutics Revenue by Company (US$ Million), 2021–2026
Table 6. Global Peptide Therapeutics Revenue Market Share by Company (2021–2026)
Table 7. Key Companies’ R&D and Operations Footprint and Headquarters
Table 8. Key Companies Peptide Therapeutics Product Type
Table 9. Key Companies General Availability (GA) Timeline for Peptide Therapeutics
Table 10. Global Peptide Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on Peptide Therapeutics revenue, 2025
Table 12. Mergers & Acquisitions and Expansion Plans
Table 13. Global Peptide Therapeutics Sales Value by Type: 2021 vs 2025 vs 2032 (US$ Million)
Table 14. Global Peptide Therapeutics Sales Value by Type (US$ Million), 2021–2026
Table 15. Global Peptide Therapeutics Sales Value by Type (US$ Million), 2027–2032
Table 16. Global Peptide Therapeutics Sales Market Share in Value by Type (2021–2026)
Table 17. Global Peptide Therapeutics Sales Market Share in Value by Type (2027–2032)
Table 18. Global Peptide Therapeutics Sales Value by Target Class: 2021 vs 2025 vs 2032 (US$ Million)
Table 19. Global Peptide Therapeutics Sales Value by Target Class (US$ Million), 2021–2026
Table 20. Global Peptide Therapeutics Sales Value by Target Class (US$ Million), 2027–2032
Table 21. Global Peptide Therapeutics Sales Market Share in Value by Target Class (2021–2026)
Table 22. Global Peptide Therapeutics Sales Market Share in Value by Target Class (2027–2032)
Table 23. Global Peptide Therapeutics Sales Value by End Users: 2021 vs 2025 vs 2032 (US$ Million)
Table 24. Global Peptide Therapeutics Sales Value by End Users (US$ Million), 2021–2026
Table 25. Global Peptide Therapeutics Sales Value by End Users (US$ Million), 2027–2032
Table 26. Global Peptide Therapeutics Sales Market Share in Value by End Users (2021–2026)
Table 27. Global Peptide Therapeutics Sales Market Share in Value by End Users (2027–2032)
Table 28. Global Peptide Therapeutics Sales Value by Application: 2021 vs 2025 vs 2032 (US$ Million)
Table 29. Global Peptide Therapeutics Sales Value by Application (US$ Million), 2021–2026
Table 30. Global Peptide Therapeutics Sales Value by Application (US$ Million), 2027–2032
Table 31. Global Peptide Therapeutics Sales Market Share in Value by Application (2021–2026)
Table 32. Global Peptide Therapeutics Sales Market Share in Value by Application (2027–2032)
Table 33. Global Peptide Therapeutics Sales Value by Region, (US$ Million), 2021 vs 2025 vs 2032
Table 34. Global Peptide Therapeutics Sales Value by Region (US$ Million), 2021–2026
Table 35. Global Peptide Therapeutics Sales Value by Region (US$ Million), 2027–2032
Table 36. Global Peptide Therapeutics Sales Value by Region (%), 2021–2026
Table 37. Global Peptide Therapeutics Sales Value by Region (%), 2027–2032
Table 38. Key Countries/Regions Peptide Therapeutics Sales Value Growth Trends, (US$ Million): 2021 vs 2025 vs 2032
Table 39. Key Countries/Regions Peptide Therapeutics Sales Value, (US$ Million), 2021–2026
Table 40. Key Countries/Regions Peptide Therapeutics Sales Value, (US$ Million), 2027–2032
Table 41. Sanofi Basic Information List
Table 42. Sanofi Description and Business Overview
Table 43. Sanofi Peptide Therapeutics Products, Services, and Solutions
Table 44. Revenue (US$ Million) in Peptide Therapeutics Business of Sanofi (2021–2026)
Table 45. Sanofi Recent Developments
Table 46. Teva Basic Information List
Table 47. Teva Description and Business Overview
Table 48. Teva Peptide Therapeutics Products, Services, and Solutions
Table 49. Revenue (US$ Million) in Peptide Therapeutics Business of Teva (2021–2026)
Table 50. Teva Recent Developments
Table 51. Novo Nordisk Basic Information List
Table 52. Novo Nordisk Description and Business Overview
Table 53. Novo Nordisk Peptide Therapeutics Products, Services, and Solutions
Table 54. Revenue (US$ Million) in Peptide Therapeutics Business of Novo Nordisk (2021–2026)
Table 55. Novo Nordisk Recent Developments
Table 56. Takeda Basic Information List
Table 57. Takeda Description and Business Overview
Table 58. Takeda Peptide Therapeutics Products, Services, and Solutions
Table 59. Revenue (US$ Million) in Peptide Therapeutics Business of Takeda (2021–2026)
Table 60. Takeda Recent Developments
Table 61. Eli Lilly Basic Information List
Table 62. Eli Lilly Description and Business Overview
Table 63. Eli Lilly Peptide Therapeutics Products, Services, and Solutions
Table 64. Revenue (US$ Million) in Peptide Therapeutics Business of Eli Lilly (2021–2026)
Table 65. Eli Lilly Recent Developments
Table 66. AstraZeneca Basic Information List
Table 67. AstraZeneca Description and Business Overview
Table 68. AstraZeneca Peptide Therapeutics Products, Services, and Solutions
Table 69. Revenue (US$ Million) in Peptide Therapeutics Business of AstraZeneca (2021–2026)
Table 70. AstraZeneca Recent Developments
Table 71. Novartis Basic Information List
Table 72. Novartis Description and Business Overview
Table 73. Novartis Peptide Therapeutics Products, Services, and Solutions
Table 74. Revenue (US$ Million) in Peptide Therapeutics Business of Novartis (2021–2026)
Table 75. Novartis Recent Developments
Table 76. AbbVie Basic Information List
Table 77. AbbVie Description and Business Overview
Table 78. AbbVie Peptide Therapeutics Products, Services, and Solutions
Table 79. Revenue (US$ Million) in Peptide Therapeutics Business of AbbVie (2021–2026)
Table 80. AbbVie Recent Developments
Table 81. Ipsen Basic Information List
Table 82. Ipsen Description and Business Overview
Table 83. Ipsen Peptide Therapeutics Products, Services, and Solutions
Table 84. Revenue (US$ Million) in Peptide Therapeutics Business of Ipsen (2021–2026)
Table 85. Ipsen Recent Developments
Table 86. Ferring Basic Information List
Table 87. Ferring Description and Business Overview
Table 88. Ferring Peptide Therapeutics Products, Services, and Solutions
Table 89. Revenue (US$ Million) in Peptide Therapeutics Business of Ferring (2021–2026)
Table 90. Ferring Recent Developments
Table 91. Merck Basic Information List
Table 92. Merck Description and Business Overview
Table 93. Merck Peptide Therapeutics Products, Services, and Solutions
Table 94. Revenue (US$ Million) in Peptide Therapeutics Business of Merck (2021–2026)
Table 95. Merck Recent Developments
Table 96. The Medicines Basic Information List
Table 97. The Medicines Description and Business Overview
Table 98. The Medicines Peptide Therapeutics Products, Services, and Solutions
Table 99. Revenue (US$ Million) in Peptide Therapeutics Business of The Medicines (2021–2026)
Table 100. The Medicines Recent Developments
Table 101. J & J Basic Information List
Table 102. J & J Description and Business Overview
Table 103. J & J Peptide Therapeutics Products, Services, and Solutions
Table 104. Revenue (US$ Million) in Peptide Therapeutics Business of J & J (2021–2026)
Table 105. J & J Recent Developments
Table 106. Aurinia Pharmaceuticals Basic Information List
Table 107. Aurinia Pharmaceuticals Description and Business Overview
Table 108. Aurinia Pharmaceuticals Peptide Therapeutics Products, Services, and Solutions
Table 109. Revenue (US$ Million) in Peptide Therapeutics Business of Aurinia Pharmaceuticals (2021–2026)
Table 110. Aurinia Pharmaceuticals Recent Developments
Table 111. BioMarin Pharmaceutical Basic Information List
Table 112. BioMarin Pharmaceutical Description and Business Overview
Table 113. BioMarin Pharmaceutical Peptide Therapeutics Products, Services, and Solutions
Table 114. Revenue (US$ Million) in Peptide Therapeutics Business of BioMarin Pharmaceutical (2021–2026)
Table 115. BioMarin Pharmaceutical Recent Developments
Table 116. Apellis Pharmaceuticals Basic Information List
Table 117. Apellis Pharmaceuticals Description and Business Overview
Table 118. Apellis Pharmaceuticals Peptide Therapeutics Products, Services, and Solutions
Table 119. Revenue (US$ Million) in Peptide Therapeutics Business of Apellis Pharmaceuticals (2021–2026)
Table 120. Apellis Pharmaceuticals Recent Developments
Table 121. Lantheus Basic Information List
Table 122. Lantheus Description and Business Overview
Table 123. Lantheus Peptide Therapeutics Products, Services, and Solutions
Table 124. Revenue (US$ Million) in Peptide Therapeutics Business of Lantheus (2021–2026)
Table 125. Lantheus Recent Developments
Table 126. CSL Vifor Group Basic Information List
Table 127. CSL Vifor Group Description and Business Overview
Table 128. CSL Vifor Group Peptide Therapeutics Products, Services, and Solutions
Table 129. Revenue (US$ Million) in Peptide Therapeutics Business of CSL Vifor Group (2021–2026)
Table 130. CSL Vifor Group Recent Developments
Table 131. Revenue (US$ Million) in Peptide Therapeutics Business of Company 40 (2021–2026)
Table 132. Company 40 Recent Developments
Table 133. Key Raw Materials Lists
Table 134. Key Suppliers of Raw Materials Lists
Table 135. Peptide Therapeutics Downstream Customers
Table 136. Peptide Therapeutics Distributors List
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
muLu

List of Figures

Figure 1. Peptide Therapeutics Product Picture
Figure 2. Global Peptide Therapeutics Sales Value, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. Global Peptide Therapeutics Sales Value (US$ Million), 2021–2032
Figure 4. Peptide Therapeutics Report Years Considered
Figure 5. Global Peptide Therapeutics Players Revenue Ranking (US$ Million), 2025
Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Peptide Therapeutics Revenue in 2025
Figure 7. Peptide Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 8. Injection Picture
Figure 9. Oral Picture
Figure 10. Other Picture
Figure 11. Global Peptide Therapeutics Sales Value by Type (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Peptide Therapeutics Sales Value Market Share by Type, 2025 & 2032
Figure 13. Agonist/Analog Picture
Figure 14. Antagonist Picture
Figure 15. Enzyme Inhibitor Picture
Figure 16. Ion Channel Picture
Figure 17. Global Peptide Therapeutics Sales Value by Target Class (US$ Million), 2021 vs 2025 vs 2032
Figure 18. Global Peptide Therapeutics Sales Value Market Share by Target Class, 2025 & 2032
Figure 19. Retail Picture
Figure 20. Hospital Picture
Figure 21. Other Picture
Figure 22. Global Peptide Therapeutics Sales Value by End Users (US$ Million), 2021 vs 2025 vs 2032
Figure 23. Global Peptide Therapeutics Sales Value Market Share by End Users, 2025 & 2032
Figure 24. Product Picture of Cancer
Figure 25. Product Picture of Metabolic Disorders
Figure 26. Product Picture of Central Nervous System
Figure 27. Product Picture of Other
Figure 28. Global Peptide Therapeutics Sales Value by Application (US$ Million), 2021 vs 2025 vs 2032
Figure 29. Global Peptide Therapeutics Sales Value Market Share by Application, 2025 & 2032
Figure 30. North America Peptide Therapeutics Sales Value (US$ Million), 2021–2032
Figure 31. North America Peptide Therapeutics Sales Value by Country (%), 2025 vs 2032
Figure 32. Europe Peptide Therapeutics Sales Value (US$ Million), 2021–2032
Figure 33. Europe Peptide Therapeutics Sales Value by Country (%), 2025 vs 2032
Figure 34. Asia Pacific Peptide Therapeutics Sales Value (US$ Million), 2021–2032
Figure 35. Asia Pacific Peptide Therapeutics Sales Value by Subregion (%), 2025 vs 2032
Figure 36. South America Peptide Therapeutics Sales Value (US$ Million), 2021–2032
Figure 37. South America Peptide Therapeutics Sales Value by Country (%), 2025 vs 2032
Figure 38. Middle East & Africa Peptide Therapeutics Sales Value (US$ Million), 2021–2032
Figure 39. Middle East & Africa Peptide Therapeutics Sales Value by Country (%), 2025 vs 2032
Figure 40. Key Countries/Regions Peptide Therapeutics Sales Value (%), 2021–2032
Figure 41. United States Peptide Therapeutics Sales Value (US$ Million), 2021–2032
Figure 42. United States Peptide Therapeutics Sales Value by Type (%), 2025 vs 2032
Figure 43. United States Peptide Therapeutics Sales Value by Application (%), 2025 vs 2032
Figure 44. Europe Peptide Therapeutics Sales Value (US$ Million), 2021–2032
Figure 45. Europe Peptide Therapeutics Sales Value by Type (%), 2025 vs 2032
Figure 46. Europe Peptide Therapeutics Sales Value by Application (%), 2025 vs 2032
Figure 47. China Peptide Therapeutics Sales Value (US$ Million), 2021–2032
Figure 48. China Peptide Therapeutics Sales Value by Type (%), 2025 vs 2032
Figure 49. China Peptide Therapeutics Sales Value by Application (%), 2025 vs 2032
Figure 50. Japan Peptide Therapeutics Sales Value (US$ Million), 2021–2032
Figure 51. Japan Peptide Therapeutics Sales Value by Type (%), 2025 vs 2032
Figure 52. Japan Peptide Therapeutics Sales Value by Application (%), 2025 vs 2032
Figure 53. South Korea Peptide Therapeutics Sales Value (US$ Million), 2021–2032
Figure 54. South Korea Peptide Therapeutics Sales Value by Type (%), 2025 vs 2032
Figure 55. South Korea Peptide Therapeutics Sales Value by Application (%), 2025 vs 2032
Figure 56. Southeast Asia Peptide Therapeutics Sales Value (US$ Million), 2021–2032
Figure 57. Southeast Asia Peptide Therapeutics Sales Value by Type (%), 2025 vs 2032
Figure 58. Southeast Asia Peptide Therapeutics Sales Value by Application (%), 2025 vs 2032
Figure 59. India Peptide Therapeutics Sales Value (US$ Million), 2021–2032
Figure 60. India Peptide Therapeutics Sales Value by Type (%), 2025 vs 2032
Figure 61. India Peptide Therapeutics Sales Value by Application (%), 2025 vs 2032
Figure 62. Peptide Therapeutics Value Chain
Figure 63. Peptide Therapeutics Cost Structure
Figure 64. Channels of Distribution (Direct Sales, and Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
den_biaoTiZhungShi

KEY QUESTIONS ADDRESSED BY THE REPORT

What is the annual compound growth rate of the global Peptide Therapeutics market size from 2026 to 2032?zhanKai
The annual compound growth rate of the global Peptide Therapeutics market is 9.0% 2026 to 2032.
Which companies rank high in the global Peptide Therapeutics market?shouQi
What was the global market size of Peptide Therapeutics in 2032?shouQi
What was the global market size of Peptide Therapeutics in 2026?shouQi
Which region is expected to have the highest market share?shouQi
den_biaoTiZhungShi

Related Reports

Peptide Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032

Industry: Medical Care

Published Date: 2026-02-14

Pages: 122 Pages

Report ld: 5493417

CHOOSE LICENSE TYPE
tip

USD 3950.00

tip

USD 5925.00

tip

USD 7900.00

Add to Cart

Add to Cart

Buy Now

Buy Now

HAVE A QUESTION?
SIMON LEE

SIMON LEE

+1-62 6295 2442

English,Chinese

Offline

HITESH

HITESH

+91-86 6998 6909

English, Hindi

Offline

TANG XIN

TANG XIN

+81-90 3800 9273

Japanese,English

Offline

SUNG-BIN YOON

SUNG-BIN YOON

+82-2883 1278

Korean, English

Offline

YUJIE TIAN

YUJIE TIAN

+86-135-2215-3954

Chinese, English

Offline

DAMON

DAMON

+86-133 1872 9947

Chinese, English

Offline

General Email:
global@qyresearch.com

REPORT COVERAGE

den_ic8

DESCRIPTION

zhankai
den_ic7

OVERVIEW

den_ic7

MARKET SEGMENTATION

den_ic7

CHAPTER OUTLINE

den_ic7

QYRESEARCH'S STRENGTHS

den_ic8

TABLE OF CONTENTS

den_ic8

TABLE OF FIGURES

den_ic8

RLEATED REPORTS

INTEREST IN THIS REPORT?

yangBenGet A Free Sample

baoJia Request For Quotation

OR

NEED A CUSTOMIZED REPORT?

DingZhiCustomized Report

biaoTi

WORLD WIDE OFFICE

application for samples

Request Sample

Custom reports

Pre-Order Enquiry

Add to Cart

Add to Cart

Buy Now

Buy Now